Gondi Kumar1, Henry Lau, Oscar Laskin. 1. Early Drug Development, Celgene Corporation, Summit, NJ 07901, USA. gkumar@celgene.com
Abstract
PURPOSE: To assess the potential for drug-drug interactions between lenalidomide and substrates and inhibitors of cytochrome P450 (CYP) isozymes. METHODS: In vitro metabolism of lenalidomide by human liver microsomes, recombinant human CYPs and human hepatocytes was evaluated. The inhibitory and inductive effects of lenalidomide on the CYP activities were evaluated in human liver microsomes and cultured human hepatocytes, respectively. RESULTS: In vitro incubation of lenalidomide with human liver microsomes, recombinant-CYP isozymes, and human hepatocytes did not result in Phase I or Phase II metabolism, confirming the low propensity of lenalidomide for metabolism in vivo in humans. In vitro, lenalidomide did not inhibit CYP isozymes in human liver microsomes and did not induce CYP activities in cultured human hepatocytes. CONCLUSIONS: Lenalidomide is not a substrate, inhibitor, or inducer of CYP group of enzymes; clinically relevant pharmacokinetic drug-drug interactions are unlikely to occur between lenalidomide and co-administered CYP substrates or inhibitors.
PURPOSE: To assess the potential for drug-drug interactions between lenalidomide and substrates and inhibitors of cytochrome P450 (CYP) isozymes. METHODS: In vitro metabolism of lenalidomide by human liver microsomes, recombinant human CYPs and human hepatocytes was evaluated. The inhibitory and inductive effects of lenalidomide on the CYP activities were evaluated in human liver microsomes and cultured human hepatocytes, respectively. RESULTS: In vitro incubation of lenalidomide with human liver microsomes, recombinant-CYP isozymes, and human hepatocytes did not result in Phase I or Phase II metabolism, confirming the low propensity of lenalidomide for metabolism in vivo in humans. In vitro, lenalidomide did not inhibit CYP isozymes in human liver microsomes and did not induce CYP activities in cultured human hepatocytes. CONCLUSIONS:Lenalidomide is not a substrate, inhibitor, or inducer of CYP group of enzymes; clinically relevant pharmacokinetic drug-drug interactions are unlikely to occur between lenalidomide and co-administered CYP substrates or inhibitors.
Authors: Chad C Bjorklund; Wencai Ma; Zhi-Qiang Wang; R Eric Davis; Deborah J Kuhn; Steven M Kornblau; Michael Wang; Jatin J Shah; Robert Z Orlowski Journal: J Biol Chem Date: 2010-12-28 Impact factor: 5.157
Authors: Jim H Hughes; Mitch A Phelps; Richard N Upton; Stephanie E Reuter; Yue Gao; John C Byrd; Michael R Grever; Craig C Hofmeister; Guido Marcucci; William Blum; Kristie A Blum; David J R Foster Journal: Br J Clin Pharmacol Date: 2019-02-27 Impact factor: 4.335
Authors: Craig C Hofmeister; Xiaoxia Yang; Flavia Pichiorri; Ping Chen; Darlene M Rozewski; Amy J Johnson; Seungsoo Lee; Zhongfa Liu; Celia L Garr; Erinn M Hade; Jia Ji; Larry J Schaaf; Don M Benson; Eric H Kraut; William J Hicks; Kenneth K Chan; Ching-Shih Chen; Sherif S Farag; Michael R Grever; John C Byrd; Mitch A Phelps Journal: J Clin Oncol Date: 2011-08-08 Impact factor: 44.544
Authors: Jim H Hughes; Richard N Upton; Stephanie E Reuter; Darlene M Rozewski; Mitch A Phelps; David J R Foster Journal: Cancer Chemother Pharmacol Date: 2019-09-06 Impact factor: 3.333